By Fineline Cube 
China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that its RenMab platform, a key component of its fully human antibody discovery platform family, has been granted an invention patent by the Japan Patent Office (JPO). This milestone underscores Biocytogen’s commitment to advancing its global intellectual property (IP) strategy and highlights the international recognition of its core technology.
RenMab Platform and Technology
RenMab mice are a cornerstone of Biocytogen’s RenMice platform family. Using its proprietary SUPCE technology, Biocytogen has replaced the variable region genes of mouse antibody heavy and light chains with human counterparts through precise in situ gene editing.
Global Patent Strategy
Biocytogen continues to actively pursue global patent protection for its RenMice platform and core technologies. To date, the platform has received patent approvals in nearly 10 countries and regions, including the U.S., China, and Japan. Approximately 40 additional patent applications are under review across 15 jurisdictions, with more approvals expected soon.-Fineline Info & Tech